COLL — Collegium Pharmaceutical, Inc.
$24.03+3.44%
Last close: · regular session
Last 60 sessions
COLL closed at $24.03 (+3.44%) on Oct 29, 2026. Float: 29.5M shares. Latest SEC filing: SCHEDULE 13G/A on Oct 29, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for COLL in the TickerWise workspace.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ
- Employees: 357
- Website: https://www.collegiumpharma.com
Latest SEC filings for COLL
Latest COLL news
- Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts Read article
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 Read article
- Collegium resolves Nucynta patent dispute with Grünenthal Read article
- COLL vs. DSNKY: Which Stock Is the Better Value Option? Read article
- Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? Read article
- Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.